Cumberland Pharmaceuticals announced a $100 million strategic transaction with Apotex Inc., selling its portfolio of FDA-approved brands to focus on developing orphan drug candidates addressing unmet medical needs. The deal, pending shareholder approval, aims to unlock shareholder value and support Cumberland's transition to a development-stage biopharmaceutical company. Cumberland's pipeline includes promising clinical programs for ifetroban, targeting rare diseases like Duchenne muscular dystrophy, systemic sclerosis, and pulmonary fibrosis, with recent FDA Fast Track designation for DMD. The company reported $9.1 million in Q1 2026 revenue and a net loss of $3.3 million, reflecting its shift towards innovation and development.
Sun Communities reported a strong Core Funds from Operations (FFO) of $1.84 per share for Q2 2026, surpassing its guidance range of $1.71 to $1.79. However, the company posted a net loss of $8.08 per diluted share, mainly due to losses from discontin...
T3 Defense's stock soared 201% following its subsidiary's expansion of defense technology into industrial materials, signaling strong growth potential. NextCure saw a 20.75% rise driven by a significant short squeeze, reflecting heavy short interest ...
Environics Analytics has named Cenker Ozhelvaci as Head of Sales for its core direct sales teams. Ozhelvaci brings extensive experience from sectors like financial services and technology, having previously led sales at Provenir and Amazon Canada. Hi...
AT&T reported better-than-expected earnings and announced a $10 billion share buyback program. Despite the positive results and buyback plan, the stock still trades at a relatively low valuation of 8 times earnings and offers a 4.6% dividend yield. T...
AstraZeneca reported a 21% increase in core earnings per share to $2.63 for Q2 2026, surpassing analyst expectations of $2.50. Total revenue rose 6% to $15.38 billion, driven by strong sales in oncology and rare disease drugs, offsetting pressure fro...
